廣告
香港股市 將在 5 小時 38 分鐘 開市
  • 恒指

    18,028.52
    -306.78 (-1.67%)
     
  • 國指

    6,439.82
    -116.28 (-1.77%)
     
  • 上證綜指

    2,998.14
    -7.30 (-0.24%)
     
  • 道指

    39,150.33
    +15.53 (+0.04%)
     
  • 標普 500

    5,464.62
    -8.55 (-0.16%)
     
  • 納指

    17,689.36
    -32.24 (-0.18%)
     
  • Vix指數

    13.20
    -0.08 (-0.60%)
     
  • 富時100

    8,237.72
    -34.74 (-0.42%)
     
  • 紐約期油

    80.59
    -0.14 (-0.17%)
     
  • 金價

    2,334.70
    +3.50 (+0.15%)
     
  • 美元

    7.8053
    +0.0005 (+0.01%)
     
  • 人民幣

    0.9297
    -0.0001 (-0.01%)
     
  • 日圓

    0.0486
    -0.0003 (-0.55%)
     
  • 歐元

    8.3411
    -0.0134 (-0.16%)
     
  • Bitcoin

    64,088.73
    -171.50 (-0.27%)
     
  • CMC Crypto 200

    1,321.53
    -38.80 (-2.85%)
     

Hims & Hers Is Selling Copycat Weight-Loss Drugs. Here’s How.

Hims & Hers Is Selling Copycat Weight-Loss Drugs. Here’s How.

A plan by Hims & Hers Health to sell legal copies of Novo Nordisk weight loss drug Wegovy is drawing pushback from the industry, and bringing new attention to an area of concern for public-health officials. Enormous demand has created shortages of Novo’s Wegovy, as well as a competing weight loss injection from Eli Lilly called Zepbound. Both companies are spending billions of dollars to increase their manufacturing capacity, but the availability of the medicines is limited in the U.S., according to the Food and Drug Administration.